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I Like the Candy, I Hate the Wrapper
The 32P Radioactive Stent
Patrick W. Serruys, MD, PhD; I. Patrick Kay, MBChB
United States patent 5059166, issued October 22,1991, to Robert and Tim Fischell, described an“intraarterial stent with the capability to inhibit
intimal hyperplasia.”1 The proponents of this patent went on
to say in their proposal: “Since radiation from a radioisotope
source is capable of selectively inhibiting the growth of
hyperproliferating cells as compared with normal cells, a
radioisotope material which forms part of the stent can be
used to decrease the rate of arterial reclosure. The radioiso-
tope could be placed inside the stent, alloyed into the metal
from which the stent is made, or preferably, it can be coated
onto the stent’s exterior surface.” So began the story of the
radioactive stent. Eight years and several animal species later,
we are becoming aware of the bright and dark sides of this
treatment modality in the human model.
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The safety and efficacy study by Albiero and colleagues2
describes the dose-related decrease noted at 6-month
follow-up of intrastent neointimal hyperplasia after implan-
tation of 32P radioactive stents at activities of 0.75 to 12 mCi.
Whereas in-stent restenosis was all but obliterated at higher
doses of radiation, intralesion restenosis was high because of
late lumen loss at the stent edges. Aptly, the authors coined
the term “candy wrapper” to describe this new restenotic
pattern. It is possible that the animal workers who implanted
the first radioactive stents observed this phenomenon. Unfor-
tunately, the significance of this finding may not have been
immediately apparent.
Historical and Dosimetric Considerations
The study by Albiero and colleagues reflects the courage of
the investigators who, despite indifferent and at times con-
tradictory results from animal work, persisted in their en-
deavor to discover whether radioactive stent implantation
would be effective in humans.
Previously, Hehrlein et al,3,4 using the rabbit iliac model,
polyisotopic 55Co (elements 55Co, 56Co, 57Co, 57Ni, and 55Fe)
with activity levels of 17.5 and 35 mCi, and later 32P stents
(activity levels of 0.5, 4, 6, and 13 mCi), had demonstrated a
dose-dependent effect of inhibition of neointimal hyperplasia
within the stent. It had already been noted that lower activity
levels were able to reduce neointimal hyperplasia, but the
effect was lost at 12 weeks, particularly at the stent ends.
Between struts and at stent ends, endothelialization occurred
more rapidly and was dose-dependent.
In the porcine coronary restenosis model of Carter et al,5
different activities of 32P-containing stents were used.
Mitchell6 makes the following observation on these findings:
“The doses delivered by the different activities of 32P were
divided into 3 categories: low (,2000 cGy), intermediate
(4000 cGy) and high (.10 000 cGy). Based on these values,
the average dose rates to the tissue over the 25-day period of
the study were: low (3 cGy/h), intermediate (6 cGy/h), and
high (15 cGy/h). It is interesting that both the high and low
doses and dose rates were effective in reducing the extent of
restenosis, whereas, the intermediate dose/dose rate was
ineffective if not worse than the control. These findings do
not conform to the findings that would be expected as dose
and dose-rate are reduced. One might expect the high dose/
dose rate to be effective and perhaps the intermediate and low
dose/dose rate to be ineffective. The fact that the low
dose/dose rate treatment was effective in this study suggests
that perhaps an inverse dose-rate effect is operative over a
narrow range of dose rates in this model.” As suggested
above, it is not only the total dose of irradiation delivered to
the tissue that is important but also the dose-rate time interval
in which radiation is delivered. This reflects the simultaneous
processes of DNA repair, concurrent with the damage in-
duced by radiation exposure. This is particularly important in
comparisons of the high dose-rates of catheter-based tech-
niques with those of radioactive stents that use low dose-
rates. An increase in the dose-rate at which certain cell lines
are irradiated in vitro demonstrates a killing effect that is most
marked between 1 and 100 cGy/min.4,7 However, at 0.6
cGy/min, there is more effective cell killing than at 0.2 or 2.6
cGy/min. This is due to cell cycle blockade. At this dose-rate,
the cells are selectively blocked at G2/mitosis, a more
radiosensitive phase of the cell cycle. Once this occurs, the
low-dose-rate treatment becomes much more efficient with
respect to killing (inverse dose-rate effect).6
We previously made the following comment on these
conflicting observations: “so far incremental doses have
always resulted in more cell death or decreased cell prolifer-
ation. We cannot exclude that there is a U-shaped dose-
response curve for endovascular radiation, but in view of all
the earlier reports, this is unlikely.”8 Of course, it is possible
that the European rabbit was more receptive to the effects of
brachytherapy than the American pig. In general, the results
derived from certain animal testing and the dose-finding
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Editorial
effect in human series of Albiero et al appear logical and are
in keeping with the general rule of brachytherapy: the more
you irradiate, the more you inhibit proliferation, up to the
point at which detrimental effects appear.
Recently, more information has become available on the
delayed endothelialization of the radioactive stent,9 with the
consequent risk of late thrombosis. Albiero and colleagues
endeavored to avoid the thrombotic sequelae of late endothe-
lialization by using longer courses of antiplatelet agents. We
are aware of only 1 episode of subacute thrombosis occurring
in humans after radioactive stent implantation to date, in
contrast to recent findings using the combination of conven-
tional stents and catheter-based radiation.10,11
Not All Radioactive Stents Are Equal:
Techniques of Stent Activation
The clinical effect of a radioactive stent may be modulated by
use of radioisotopes with different half-lives, energy, activity,
and penetration. Consequently, in the interpretation of results
originating from different radioactive stent trials that used
different isotopes, extrapolation between stents and isotopes
may be inappropriate. The trials discussed above used 2
different techniques to make the stents radioactive: (1) direct
ion implantation (that used by Isostent to create the 32P stent)
(Isostent Inc, Belmont, Calif, personal communication):
phosphorus-containing 32P isotope produced by neutron acti-
vation was inserted into the ion source of an implanter.
Ionized 31P and 32P atoms were accelerated and separated by
a magnet so that only the 32P was implanted directly onto the
stent surface. (2) Bombardment with charged particles (as
used by Hehrlein et al)3,4: the stents were placed into a
cyclotron and bombarded with deuterons. Metallic stent
particles were transformed into several radioisotopes. Later,
proton bombardment was used to reduce the high-energy
g-radiation emitted by the stents.
Other methods currently available include electrodeposi-
tion (a technique for the manufacture of a g-radiation–
emitting stent) and finally, isotope-emitting gold and phos-
phorylcholine stents. Clear advantages of 1 technique over
another will be the subject of future consumer reports.
The 32P Stent: An Antirestenotic Stent Using
an Electron-Beam Fence
In our enthusiasm to control vessel recoil and remodeling
after balloon angioplasty, stent implantation has become
increasingly popular. With conventional stenting, we have
eliminated recoil and remodeling as components of the
restenotic process. However, this has been at the cost of
exacerbating neointimal proliferation secondary to chronic
vessel wall irritation, leading to in-stent restenosis.12
As a means of preventing neointimal proliferation, the idea
of creating an electron-beam fence has been raised. Simply,
the idea is to place radioactivity where it should be in the first
place: at the endoluminal surface, generating a fence that
should “fry” any smooth muscle cells or myofibroblasts
trying to reach the endoluminal cavity created by the stent.13
In this model, the concept of irradiating a target volume, as is
desirable with cancer or catheter-based technologies, may not
be relevant. Catheter-based brachytherapy involves the use of
a single-hit, high-dose administration of intracoronary radia-
tion. It seeks to target a volume of myofibroblasts and smooth
muscle cells within the adventitia by irreversibly altering the
DNA, such that on cell division, death will occur. This clearly
decreases the reproductive capacity of the adventitia as a unit,
and consequently, the potential for restenosis. Using the
radioactive stent approach, we do not have to neutralize the
huge reservoir of quiescent myofibroblasts lying dormant in
the adventitia. Prevention of the migration and invasion of
myofibroblasts occurs because of the continuous and low
dose-rate, as witnessed by Albiero et al, adding credence to
the concept of the electron-beam fence. This takes place
regardless of the bulk of the atherosclerotic plaque and extent
of penetration of the radiation. Equally, it occurs despite the
eccentric placement of the radioactive stent within the vessel.
In a preliminary report, the Milan group14 demonstrated that
a heterogeneous adventitial exposure (maximum dose,
437863078 cGy/14 d; minimum dose, 5636360 cGy/14 d;
range, maximum dose, 644 to 12 210 cGy/14 d; range,
minimum dose, 153 to 1461 cGy/14 d) still results in a
homogeneous stent response with respect to the formation of
neointimal hyperplasia.
Initially, basic scientists and radiotherapists perceived the
concept of an electron-beam fence as being a fantasy created
by cardiologists, objecting that it was not realistic. Ulti-
mately, however, the proponents of the fence may just be
correct.
Application of the concept of an electron-beam fence to the
stent edge, however, makes one aware of its potential
Achilles’ heel. The range of the stent radioactivity is limited,
and whereas those cells behind the stent struts may be well
fenced at the doses discussed, cells proximal and distal to the
extremity of the stent, in injured areas treated by the balloon
(up to 3 mm outside the stent; personal communication,
Isostent), may not be effectively covered by the range of the
stent radiation. The latter phenomenon has been described in
radiotherapeutic terms as “geographical miss”: the mismatch
between the irradiated and injured area15 (Figure 1).
The Problem of the Candy Wrapper and Its
Prevention: Is the Candy Wrapper Another
Oculostenotic Illusion?
Stent-edge renarrowing occurs after conventional stent im-
plantation.16 This may not be angiographically visible, be-
cause the luminal ingrowth at the stent edges is in juxtapo-
sition to the neointimal hyperplasia within the stent,
producing a smooth contour on the luminogram. In contrast,
after radioactive stenting, a visual gradient at the extremities
becomes apparent, because nothing will grow within the
stent, which makes all edge restenoses obvious.
In the study by Albiero et al, we note that lesions received
a further percutaneous intervention on the basis of whether
there was evidence of .50% intralesion angiographic steno-
sis. It may be that a word of caution is required in the
assessment of the stent-edge lesion so as not to be seduced
into believing that all such stenoses require treatment, given
that the transition from the pristine stent lumen to the stent
edge may appear great.
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The propensity for edge restenosis to occur at either the
proximal, distal, or both edges also remains ill-defined. It is
conceivable that after conventional stenting, stent-edge reste-
nosis with luminal narrowing adjacent to a pristine stent
lumen could result in a rheological condition with consequent
alteration of shear stress, promoting what is finally viewed as
a candy wrapper.
Identifying the mechanism by which the candy wrapper
occurs may permit a more focused strategy concerning its
treatment. Using intravascular ultrasound, the authors de-
scribe an increase in plaque/media in the region 1 to 3 mm
immediately proximal and distal to the stent and a decrease in
the external elastic membrane from 4 to 10 mm. To combat
these identified vascular changes that induce stent-edge
restenosis, various modifications to existing radioactive stent
morphology could be proposed: (1) the square-shouldered
balloon, (2) the cold-end stent, (3) the hot-end stent, (4) a
hybrid radioactive stent/radioactive catheter–based system,
(5) a self-expanding radioactive stent, and finally (6) the
g-stent.
The appropriateness of any one of these suggestions will
depend on what underlies the change in plaque volume and/or
shrinkage in vessel size. As usual in medicine, the problem is
likely to be multifactorial, with confounding factors. At first
sight, the elements may be portrayed schematically as in
Figure 2.
Is the edge effect secondary to low-dose radiation at the
margins of the stent, or due to balloon injury at the stent
edges, or a combination of the 2? In this study, the univariate
analysis suggests that those vessels with a higher final
balloon-to-artery ratio, smaller reference lumen diameter, and
smaller final minimum lumen diameter by angiography are
most susceptible to adverse stent-edge morphological change.
If the edge effect is the result of balloon-induced trauma
and low-dose radiation (Figure 3A), then limiting the trauma
outside the stent and expanding the irradiated area beyond the
injured area should be attempted. Conceivably, the most
practical approach may be to use a square-shouldered balloon
(to minimize the injured area outside the stent) in combina-
tion with an extension of the area of irradiation beyond the
injured area (“hot-end stent”) (Figure 3B).
If the candy wrapper were purely the result of negative
remodeling induced by low-dose radiation in an injured area,
then the lengthening of the stent by a nonradioactive, cold-
end stent would be a logical solution to prevent remodeling at
the extremities (Figure 3C). If plaque constitutes a large
percentage of the healing process manifested by the candy
wrapper, then cold-end stent implantation is unlikely to work.
Similarly, neointimal proliferation may occur at the edges of
the radiation within the stent if this treatment modality is
used.
A more elaborate, sophisticated approach would be the
hybrid combination of a radioactive stent with the use of
catheter-based radiation. The sources could be incorporated
on the shaft of the balloon at the balloon extremities (Figure
3D). This approach would ensure that the injured area
receives appropriate radiation.
If the candy wrapper is the result of an aberrant response by
noninjured healthy or diseased tissue subjected to radiation,
then this may suggest that low-dose radiation has a stimula-
tory effect on noninjured tissue.17 This would be the worst
possible scenario, because clearly, noninjured healthy or
diseased tissue will always be irradiated at some stage.
In the event that excessive vascular remodeling is present
after hot-ended or hybrid therapy, then a self-expanding
nitinol radioactive stent may play a useful role (Figure 3E).
The g-stent would have better tissue penetration than the
b-emitting rivals. However, the energy generated by the
former will be a drawback, with increased radiation exposure
to patients, relatives, and personnel. It is conceivable that a
low-energy, g-radiation–emitting stent would minimize this
Figure 1. Dose representation for a 3.0-mm-
diameter P-32 BX Isostent with activity level 4.2
mCi measured at 1 mm from stent struts. y axis:
Total dose to tissue in Gy. x axis: Vertical line rep-
resents edge of stent. Area to right of vertical line
is within stent. Area proximal (or distal) to stent is
depicted to left of vertical line. Maximal balloon
overhang is described to a total of 2.7 mm axially.
Each isodose curve describes dose delivered to
tissue by stents of different activity levels (24, 36,
and 48 mCi), both within and proximal/distal to
stent. Model assumes that a dose of 30 Gy is
required to inhibit neointimal proliferation. Note
that as stent activity decreases, dose delivered to
tissue proximal/distal to stent is no longer suffi-
cient to cover area injured by balloon.
Figure 2. Multifaceted interaction that creates candy wrapper.
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environmental risk, yet provide adequate clinical effect.
Further scientific exploration of this area is clearly justified.
Conclusions
Although a decade has elapsed since the inception of radioactive
stenting, we are now beginning to understand that this treatment
modality is indeed a double-edged sword. The path of evolution
is clearly a slow one; meticulous work has been performed to
clarify the efficacy of the radioactive stent. Albiero and col-
leagues have pointed us in a new direction, beyond the stent
itself, and that is to carefully analyze the effect of injury and
low-dose radiation on vessel healing at the stent edge. The true
sweetness of the candy will only be appreciated once the
pathophysiology of stent-edge restenosis is understood.
Figure 3. A, Illustration of a balloon-
expandable BX stent. Radiation is
depicted in orange. Note that trauma to
vessel wall extends beyond that of radi-
ation. B, Square-shouldered balloon lim-
its area of injury, whereas radiation from
hot-ended stent extends to normal/unin-
jured tissue. C, Cold-end stent with radi-
ation limited to central area. D, Hybrid
radioactive stent with catheter-based
sources at each end to ensure that
injured area receives adequate radiation
coverage. E, Self-expanding radioactive
nitinol stent.
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